Wockhardt is currently trading at Rs. 275.10, up by 16.05 points or 6.20% from its previous closing of Rs. 259.05 on the BSE.
The scrip opened at Rs. 265.00 and has touched a high and low of Rs. 295.50 and Rs. 265.00 respectively. So far 588590 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 516.00 on 16-Jan-2019 and a 52 week low of Rs. 230.00 on 09-Oct-2019.
Last one week high and low of the scrip stood at Rs. 295.50 and Rs. 243.50 respectively. The current market cap of the company is Rs. 3046.32 crore.
The promoters holding in the company stood at 72.40%, while Institutions and Non-Institutions held 5.41% and 22.18% respectively.
Wockhardt has received approval from Indian drug regulator -- Drug Controller General of India (DCGI) for 2 new antibiotics, EMROK (IV) and EMROK O (Oral), which is used to treat acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India. The new drug will target superbug like Methicillin resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: